sanofi acquisit bioverativ accret
price month
price rel chart measur perform
close
spot exchang rate
morn sanofi announc agre acquisit
bioverativ product focus haemophilia rare blood
premium bioverativ current share price sanofi believ acquisit
immedi accret accret
howev forecast stand-alone bivv ep declin see
peak accret fall back low interest rate
surpris accret spend equival buy
back would accret team recent initi coverag
bivv
strong strateg fit line strategi bioverativ market product
haemophilia fit well sanofi rare diseas
strategi exist pipelin drug fitusiran believ potenti
sale synergi product includ eloct haemophilia
alprolix haemophilia sanofi leverag presenc especi
emerg market eloct cs forecast peak sale
us ex-u respect alprolix cs
assum peak sale us plu ex-u
forecast po fitusiran partnership alnylam
confer call today uk cet estimate detail
 present avail sanofi ir webpag
catalyst risk result feb praluent odyssey
readout cemiplimab basal cell carcinoma isatuximab anti-
pomalyst data relapsed/refractori multipl myeloma
valuat sanofi trade pe discount peer
ev/npv sanofi trade discount global peer
valuat metric
price-to-earnings rel local market
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
sanofi-aventi pharmaceut group engag research
develop manufactur market healthcar product
vaccin sanofi pasteur
blue sky scenario assum full pipelin success stronger
growth rate diabet
grey sky assum pipelin success greater declin
diabet driven greater gener competit lantu poor
uptak lixilan
price rel chart measur perform
close
spot exchang rate
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
sanofi acquir bioverativ
morn sanofi announc agre acquisit bioverativ
product focus haemophilia rare blood disord propos
purchas price would repres premium bioverativ current share
price believ bioverativ strong strateg fit sanofi exist platform
key product
eloct haemophilia first prolong recombin haemophilia therapi
reduc frequenc bleed episod prophylact infus everi three
five day eloct cs forecast peak sale us
ex-u respect
alprolix haemophilia first prophylact haemophilia therapi reduc
bleed episod weekli infus alprolix cs assum peak sale
us ex-u
agglutinin diseas demonstr strong result
phase clinic trial new smid-cap biotech team believ effici trial
design set stage data potenti approv team
assign probabl peak sale us
believ potenti sale synergi product sanofi
leverag presenc emerg market marketing-might develop
market drive sale addit believ sanofi leverag exist bioverativ
platform fitusiran
fitusiran haemophilia follow restructur alnylam deal
begin year sanofi global right fitusiran haemophilia
pay alnylam tier royalti global sale sanofi believ leverag
bioverativ clinic commerci expertis maximis potenti product cs
assum probabl peak sale us/eu
probabl ex-us/ex-eu peak
merger model suggest accret
sanofi believ bioverativ acquisit immedi accret
accret merger model assum
debt financ
sanofi boost eloct alprolix sale base consensu forecast
sanofi well posit drive faster eloct alprolix ramp
achiev pre-tax profit increment sale
base assumpt assum full acquisit price see
posit accret sanofi immedi forecast stand-alone bivv ep
declin see peak accret fall back
base merger model figur estim
accret increment sale sg save
accret increment sale larg ex us reduc
accret increment sale cost save off-set
accret increment sale save split
sg higher save offset declin bivv stand-alone sale
altern share buy-back would give accret given low
cost borrow virtual deal accret therefor also model
compani spend net cost buy bivv share buy-back reflect
opportun cost deal case see ep accret buy-back
cs incom statement million except ep martin auster non- revenu collabor expens cog non non non product product product total total opex non incom op incom expens tax tax benefit expens tax rate non incom non ep ep ep ep growth charl martineau pm univers toronto
figur cs sanofi bioverativ merger model
sanofi biiv non rate bivv extra salessavings/financeproforma sanofi bivv extra salessavings/financeproforma sanofi bivv extra salessavings/financeproforma sanofi bivv extra salessavings/financeproforma sanofi bivv extra salessavings/financeproforma agglutinin prob net buy back use buy-back charl martineau pm univers toronto
haemophilia increasingli competit
expect current haemophilia market becom increasingli competit
roch hemlibra potenti chang way haemophilia patient treat
launch longer act factor product
develop tfpi shire novo bayer involv
develop sirna fitusiran
team recent initi survey haemophilia patients/caregiv
patient prefer primari driver product uptak patient survey
report high degre autonomi treatment decis report health
insur restrict major hurdl date
major patient comfort switch treatment achiev greater
administr conveni respond report comfort
switch therapi report switch treatment past
year primari reason patient switch past year administr
conveni reduct bleed rate directli contrast
convent wisdom articul clinician remain troubl
challeng haemophilia
hiv hcv
haemophilia patient
issu dramat
treatment
administr burden appear greatest area dissatisfact current
therapi patient report less fulli satisfi dose
frequenc common reason patient look switch
current therapi
haemophilia patient find novel therapeut compel haemophilia
patient express interest subcutan product dose everi week
hemlibra fitusiran express interest take drug within year
product market meanwhil patient express interest
gene therapi though patient would interest adopt product
within first year market see chart detail
lower interest level gene therapi appear larg due parent uncomfort
administ gene therapi children assum adult market
initi target market gene therapi pediatr uptak follow longer-
term safeti durabl data accru
haemophilia remain attract opportun novel therapeut despit
compar better extend half-liv haemophilia space
haemophilia patient express interest subcutan product administ
everi week patient interest gene therapi similar
haemophilia space uptak gene therapi like gradual
novel therapeut may use year though suspect
matur awar exist clinic data could increas enthusiasm longer-
chang forecast
made minim chang stand alon sanofi forecast updat
fx beyond includ bioverativ acquisit full
number acquisit complet
figur chang forecast
net sale chang chang chang chang total chang cs chang busi suiss compound-annual-growth-rate declinewil bi sale sale oper growth margin margin sanofi new drug vs progress save progress save off-set launch cost gross cost save n/c gross cost save n/c eur bncontinu invest late stage programscontinu grow op overal grow similar cer rate growth cer constant oper although much reinvest jv tax busi growth lc stabl stabl stabl impactcurr charl martineau pm univers toronto
figur eu us major pharma compar valuat
sensitivitylowpralu odyssey cv data isatuximab/ pomalidomide/dex rr data reg data us filinglixilan-g data vs comp datasotagliflozin type diabet us sq cell carcinoma us approv start rm dupilumab asthma us agonist obes poc datadupilumab ad data/fil dupilumab nasal sale growthl ep growthdiv yield sharenpv/ shareabbvi squibb lilli co major averag ex nordisk major averag ex premium/ discount major averag ex charl martineau pm univers toronto
product sale eur sale oper product oper profit op incom op incom net profit rate associ incom incom charg earn relat share data share outstand fd cs ep ep lc consolid charl martineau pm univers toronto
compani mention price
rebekah harper jo walton matthew weston phd certifi respect compani secur individu analyz
view express report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
